Drug Trial Radar · NCT06987097
Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension
Last checked: Nov 20, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
410
Planned (sponsor's estimate)
Start
May 15, 2025
Primary completion
Feb 28, 2028
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 23, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled clinical trial.
Conditions
- Pulmonary Arterial Hypertension (PAH)
Interventions
AmbrisentanDrug
After two weeks of initial treatment, the study drugs' dose will be increased to two tablets per day (10 mg/day). If the patient cannot tolerate the increased dose (e.g., experiencing headache, dizziness, palpitations, hypotension, or other drug-related symptoms or signs), the dose will be reduced to 5 mg/day. If the study drug has reached the maximum allowable dose (two tablets/day) and the patient shows signs of worsening PAH or right heart failure, the clinician may decide to add diuretics (with the type and dosage left at the referring physician's discretion). The number and percentage of patients requiring diuretic combination therapy in both groups will be recorded. Other baseline treatment medications will remain unchanged through follow-up duration.
PlaceboDrug
Placebo tablet (one to two tablets corresponding to one to two verum tablets). Administration: Placebo will be administrated orally with or without food intake in the morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy endpoint is the composite of pulmonary hypertension progression at 12 monthsTime frame: baseline,12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.